Kingston, Ontario, May 2012 – Octane Medical Group has entered into a partnership with Aesculap Biologics, LLC, a subsidiary of the multinational Aesculap Inc., (a B. Braun company) one of the world’s largest orthopedic companies with a focus on innovative spine and orthopedic treatments.
The partnership is an important step forward in Octane and Aesculap’s goal of bringing automated production of living-tissue orthopedic implants into clinical use on a global scale, says Tim Smith, CEO of Octane Medical Group. The biological properties of these living implants allow for integration into the implant site to accelerate healing with minimal risk of biological rejection and subsequent revision surgery.
The living implants are now in clinical trials focusing on knee cartilage injuries.
For press inquiries please contact Renee Thibodeau.
Cocoon™ is a patient-scale cell therapy system that forms the core of a series of versatile cell and tissue therapy production systems. Unlike other bioreactor systems, this platform integrates multiple steps, including upstream and downstream processing. From cell source isolation and cell expansion, through to cell collection, cell washing and final product formation – all in a closed, single-use disposable cassette
Coupled with advanced bioreactors, biosensor feedback and innovative cell scaffolds, this cell culture and tissue engineering platform opens up an array of clinical applications. Cocoon is an integrated turnkey production solution that can be configured as a compact but powerful system with a small footprint, or as a multi-patient system for ultra-efficient, enterprise-level deployment. Please read more about our game-changing innovations in regenerative medicine .
Kingston, Ontario, June 2, 2022 – Octane Exo Inc., an Octane Medical Group venture, has achieved a breakthrough in medical implant technology with Octane HyperPEEK, an advanced biocomposite proven to enhance bone regeneration with the goal of enhanced integration and stability.
March 2, 2022
Kingston, Ontario, 15 December 2020 – Octane Medical Group has expanded its state-of-the-art facility in Kingston, Ontario Canada. The 40,000-square-foot building, which Octane purchased in 2011, houses the company's head office and features regulated biolabs for biomaterial and biologics discovery programs including cell therapy research and development, a ...
December 15, 2020
Maine, USA, 18 March 2020 – Octane innovations in tissue engineering, personalized medicine and automated living implant production have earned one of the highest Edison Awards, winning Gold in the Medical / Dental Cellular Research category. The Gold award recognizes AUTOGRAFTA™ living graft technology and the ability to ...
March 18, 2020
Basel, Switzerland, 29 October 2018 – Lonza announced today the acquisition of a controlling stake in Octane Biotech, with the right to acquire full ownership. The increase in equity share will allow Lonza to further develop the technology to support the growing need for scalable autologous manufacturing. Octane ...
October 29, 2018